Refine
Has Fulltext
- yes (2)
Is part of the Bibliography
- yes (2)
Document Type
- Journal article (1)
- Doctoral Thesis (1)
Language
- English (2) (remove)
Keywords
- Honey bee (2) (remove)
Non-target effects of a multiple insect resistant Bt-maize on the honey bee (Apis mellifera L.)
(2011)
Honey bee pollination is an ecologically and economically important ecosystem service. New methodological developments are needed to research the underlying factors of globally observed bee losses. The honey bee (Apis mellifera) is a key non-target arthropod species for environmental risk assessment of genetically modified (GM) crops. For GM-crop risk assessments, mainly methods for monitoring adult honey bees under laboratory conditions are documented. However, protocols with robust methods for standardized colonies or in vitro reared honey bee larvae are currently lacking. Within the research, presented in this this dissertation, multiple methodological developments are achieved; a mortality trap (Chapter II), a ‘full life cycle test’ (III), a novel in vitro rearing methodology (IV), a standardized in vitro test for Bt-pollen (V), a mixed toxicity test for purified transgenic proteins (VI), and a bacterial flora test with pollen digestion rate monitoring (VII). Overall, the studies did not indicate a detrimental effect caused by Bt-maize pollen, or by purified Bt-proteins at worst case exposure levels. Considering the risk for honey bees and larvae, we conclude that the tested Bt-maize Mon89034xMon88017 is not likely to cause harm to honey bee colonies. The study methods presented are highly recommended for future environmental risk assessment studies testing GM-crop biosafety on honey bees.
Background
Referring to individuals with reactivity to honey bee and Vespula venom in diagnostic tests, the umbrella terms “double sensitization” or “double positivity” cover patients with true clinical double allergy and those allergic to a single venom with asymptomatic sensitization to the other. There is no international consensus on whether immunotherapy regimens should generally include both venoms in double sensitized patients.
Objective
We investigated the long-term outcome of single venom-based immunotherapy with regard to potential risk factors for treatment failure and specifically compared the risk of relapse in mono sensitized and double sensitized patients.
Methods
Re-sting data were obtained from 635 patients who had completed at least 3 years of immunotherapy between 1988 and 2008. The adequate venom for immunotherapy was selected using an algorithm based on clinical details and the results of diagnostic tests.
Results
Of 635 patients, 351 (55.3%) were double sensitized to both venoms. The overall re-exposure rate to Hymenoptera stings during and after immunotherapy was 62.4%; the relapse rate was 7.1% (6.0% in mono sensitized, 7.8% in double sensitized patients). Recurring anaphylaxis was statistically less severe than the index sting reaction (P = 0.004). Double sensitization was not significantly related to relapsing anaphylaxis (P = 0.56), but there was a tendency towards an increased risk of relapse in a subgroup of patients with equal reactivity to both venoms in diagnostic tests (P = 0.15).
Conclusions
Single venom-based immunotherapy over 3 to 5 years effectively and long-lastingly protects the vast majority of both mono sensitized and double sensitized Hymenoptera venom allergic patients. Double venom immunotherapy is indicated in clinically double allergic patients reporting systemic reactions to stings of both Hymenoptera and in those with equal reactivity to both venoms in diagnostic tests who have not reliably identified the culprit stinging insect.